Compare Smith & Nephew plc (SNN) vs United Microelectronics Corp (UMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs United Microelectronics Corp — how do they compare? Smith & Nephew plc trades at $27.29 (market cap $11.10B), while United Microelectronics Corp trades at $23.27 (market cap $58.02B). The key difference: United Microelectronics Corp is far larger — about 5.2× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold Smith & Nephew plc for 120 Days and United Microelectronics Corp for 42 Days on average.
| SNN | UMC | |
|---|---|---|
Market Cap | $11.10B | $58.02B |
Volume | 1,051,703 | 11,897,809 |
Sector | Health | Technology |
52-Week High | $37.17 | $28.02 |
52-Week Low | $26.42 | $7.02 |
Typical Hold Time | 120 Days | 42 Days |
Enterprise Value | $14.13B | $55.10B |
Dividend Yield | 2.95% | 1.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNN trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue and net income have grown steadily, reaching $6.16B and $625M in 2025, respectively, with improving margins. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. However, cash flow volatility and mixed analyst sentiment pose challenges.
The stock presents a value opportunity with reasonable valuation ratios (P/E 18.34, P/S 1.85), but risks include competitive pressures and recent CFO departure. Analyst consensus is cautious, with 65% hold ratings. Upside depends on execution of growth initiatives amid market headwinds.
UMC trades at $23.31, up 0.52% with a bullish technical signal despite mixed moving averages. The company shows strong profitability with 32.75% net margin and 21.03% ROE, though revenue growth has moderated from 2022 peaks. Recent earnings beats and a Zacks Strong Buy upgrade (September 17, 2026) highlight positive momentum, while cash flow turned positive in 2025 after two years of outflows.
The stock presents growth potential with expanding AI opportunities and strong 22/28nm demand, but faces risks from semiconductor cycle volatility and competitive pressures. Analyst consensus is mixed with 27% buy ratings versus 20% sell, suggesting cautious optimism amid elevated valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
